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Purpose/Objective: According to current evidence 
radiotherapy (RT) should be delivered to 50% of all cancer 
patients. In order to use this benchmark value to plan for RT 
capacity (i.e. linear accelerators and staff) in a given 
population it is necessary to account also for the proportion 
of repeat RT courses given after the first radiation 
treatment. The aim of the study was to determine the 
patterns of re-treatment for the cohort of patients who 
received their first RT course in 2009 in a RT department 
with a stable catchment area of 1.25 million inhabitants.  
Materials and Methods: From the institutional RT database 
the following information was retrieved for all new RT 
patients in 2009: Start date of first treatment course and all 
subsequent courses, number of fractions and RT technique in 
each course, cancer diagnosis, age, and intention of the 
treatment (curative including SBRT and prophylactic RT or 
palliative). The number of patients receiving their first RT 
course in 2009 (#first courses) and the total number of re-
irradiation courses delivered until now (#re-irradiation 
courses) were determined and the mean number of re-
treatments was calculated as #re-irradiation courses /#first 
courses.  
Results: The median age at first course was 65 y (range 5 mo-
95 y). Total #first courses in 2009 were 2666 (1691 curative 
RT and 875 palliative RT). Breast cancer (46%), prostate 
cancer (14%) and head and neck cancer (9%) were the three 
most common diagnoses for patients treated with curative 
intent in their first course, whereas lung cancer (38%), 
prostate cancer (10%) and breast cancer (8%) were the most 
common diagnoses when the intent was palliative. Total #re-
irradiation courses were 667 resulting in a mean number of 
re-treatments of 0.25 per patient (664/2666). The proportion 
of patients re-treated at least once was 18% (475/2666 
patients), and three or more courses were given to 133 
patients (5%). The maximum number of courses was 8 (one 
patient). The median time between the first and the second 
course was 553 and 144 days for patients treated initially 
with curative intent and palliative intent, respectively. The 
intent at the second treatment course was palliative for 78% 
of the patients and curative for 22% of the patients; 29 
patients were treated with curative intent in both the first 
and second course. Breast cancer was the most common 
diagnosis in that group with 13 patients either treated for a 
second breast cancer or another cancer. In total 36 of the 
2666 patients (1.3%) were later treated with RT for a new 
cancer diagnosis.  
Conclusions: With a follow up period of 5 years the re-
irradiation proportion was found to be 25% and the 
proportion of patients re-treated was 18%; these numbers are 
in good agreement with other published series and will be 
useful for the future planning of radiotherapy services.  
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Purpose/Objective: During 2009-2011, external peer review 
clinical audits for breast cancer radiotherapy was carried out 
at nine radiotherapy centres in Norway. The purpose was to 
assess compliance with the national radiotherapy guidelines 
regarding treatment planning for post-operative left sided 
breast cancer. All radiotherapy departments volunteered to 
take part in the audits. The audits were organized as a joint 
project between the Norwegian Breast Cancer Group (NBCG) 
and the quality assurance group in radiotherapy (KVIST) at 
the Norwegian Radiation Protection Authority. 
Materials and Methods: The audit topic was post-operative 
left sided breast cancer radiotherapy, focusing on indication 
and radiotherapy treatment planning. The audit standard was 
the national guidelines for breast cancer treatment 
(developed by NBCG). A set of audit criteria was developed 
to evaluate the clinical practice against the national 
guidelines. A total of 180 treatment files were audited by 
auditor groups composed of oncologists, medical physicists 
and RTTs. The audit findings were grouped to analyse the 
degree of guideline compliance for indication, treatment 
technique, delineation of treatment volumes and organs at 
risk, and dose related parameters. 
Results: Over all, the auditors evaluated the indication, 
delineation, treatment planning qualitatively to be in 
accordance to the national guidelines without, or with minor 
deviance, in 87% of the cases. The treatment planning was in 
accordance with the guidelines for indication, treatment 
technique and lung delineation in 98% of the cases, with 
minor deviations in 2%. For delineation of the clinical target 
volume (CTV) and the heart, minor deviations were found in 
44% of the cases, major deviations in 6%. 
The dose distribution to the CTV was in accordance with the 
guidelines in 89% of cases, with minor deviations in 11%. A 
minimum dose to CTV (breast/breast wall) of at least 95% of 
prescribed dose (D98% ≥95%) was attained in 39%, whereas D98% 
≥90% was attained in 93% of the cases. 
Conclusions: The audits showed that for a large majority of 
cases, the radiotherapy was planned in accordance to the 
guideline principles. To define and delineate the target 
volumes and the heart, and to obtain optimal dose 
distributions are challenging tasks, for which improvements 
are still desirable.  
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Purpose/Objective: With the rapid growth of health 
expenditure, economic data have received increasing 
importance as source of information for decision makers. This 
is also true in technology-intensive sectors, such as 
radiotherapy, where initial capital investment is large and 
human resources important. To understand and quantify the 
evolution of radiotherapy costs it is necessary to be clear on 
which resources are included and how they have been 
combined to compute the cost. 
Materials and Methods: A systematic literature review on 
cost computation studies in radiation therapy from 2002-2013 
was conducted on Medline and Embase with the following 
search criteria: population: focus on external beam 
radiotherapy (EBRT); intervention: costing exercise using the 
departmental perspective and including at least personnel 
and equipment costs; outcome: cost of either radiotherapy 
treatment, activity or fraction(s), and/or cost of an entire 
radiotherapy department and/or cost of a specific cancer 
type including treatment with EBRT. To be included the 
article had to accurately describe the costing methodology. 
Computation studies based on charges and reimbursement 
were excluded. 
Results: Of the 961 retrieved studies only 15 matched our 
search criteria, reasons for exclusion are as shown by the 
flowchart (fig 1). The most important reason for exclusion 
was the lack of formal cost computation (n=511) in the first 
S26                                                                                                                                         3rd ESTRO Forum 2015 
 
review rounds. With the in-depth review, articles did not 
meet inclusion because of invalid intervention (13 cost 
computation studies referring to costs described in a previous 
publication, 7 literature reviews, 10 articles not formally 
describing cost calculation) or design (n=11)  .  
 
Among the selected studies (table 1), the scope of the 
calculation varies from a comprehensive departmental 
perspective to disease-, treatment- and activity-specific 
calculations (e.g. respiratory-gated RT). Their costing 
methodologies range from detailed micro costing approaches 
(n=5) to the pragmatic activity-based costing (ABC, n=4) and 
time-driven activity-based costing (TD ABC, n=1) methods. 
Besides these established accounting methods, five studies 
developed “home-made” approaches. Not surprisingly, costs 
found in these studies vary greatly. 
 
 
 
Conclusions: While the advantages of ABC and TD-ABC for 
cost analysis have been established in the cost accounting 
literature, only one third of the studies identified have 
adopted one of these methodologies. Just as clinical studies, 
sound cost calculations require high quality input data and an 
appropriate costing methodology in order to facilitate 
comparison across studies. Robust costing exercises are a 
necessary basis to perform full economic evaluations and to 
allow accurate reimbursement setting, both key in the 
optimal allocation of health care resources.  
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Purpose/Objective: External beam radiotherapy is frequently 
used to palliate pelvic symptoms of castration resistant 
prostate cancer (CRPC). Documentation of palliative effect, 
toxicity and a recommended treatment schedule are lacking. 
The aims of the study were to evaluate changes in symptom 
severity, quality of life (QOL) and degree of toxicity among 
patients with CRPC following palliative pelvic radiotherapy 
(PPRT). 
Materials and Methods: Patients with CRPC and a 
symptomatic pelvic mass who were prescribed PPRT with 30-
39 Gy in 3 Gy fractions were eligible for inclusion. Treatment 
volume included the primary tumor and/or pelvic lymph node 
metastases as clinically indicated. Subjects were asked to 
identify a target symptom (TS), defined as their principal 
pelvic complaint requiring palliation. The primary outcome 
was patients' self-reported TS severity relative to baseline, 
12 weeks after PPRT. Patient-reported symptoms and QOL 
(measured using EORTC QLQ C30 and PR25) were assessed 
before, at the end of, and 6 and 12 weeks after PPRT. 
Results: Forty-seven patients were included and 40 were 
evaluable at the 12 week follow-up. Median age was 79 years 
(60–93). Median radiotherapy dose delivered was 36 Gy (27–
39). Lower urinary tract symptoms (LUTS) (n=21), 
macroscopic hematuria (n=12), and pelvic pain (n=9) were 
the most common TS. 28/40 (70%) evaluable patients 
reported that their TS had either resolved or improved 12 
weeks after PPRT and in an additional 10/40 (25%), the TS 
severity was unchanged. Forty-one of the 47 included 
patients (87%) reported complete resolution or improvement 
of the TS at at least one of the three follow-up visits. 
Hematuria responded most rapidly and consistently with all 
evaluable patients reporting improvement or resolution at 12 
weeks. The course of LUTS response was more variable, with 
8/18 (44%) patients reporting improved or resolved LUTS at 
the 12 week follow-up. Pelvic pain relief 12 weeks after PPRT 
was experienced by 7/9 (78%) patients who identified it as 
their TS while their use of opioids decreased. Non-target 
pelvic symptom severity decreased over the course of the 
study. Clinically relevant improvement in global QOL score 
(50-66.7 points; p=0.032) was seen 6 weeks after 
radiotherapy and otherwise remained stable at follow-up 
visits. There was no grade 4 toxicity. 
